购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空

Nintedanib esylate

产品编号 T5001Cas号 656247-18-6
别名 乙磺酸尼达尼布, Intedanib, BIBF 1120 (esylate), 尼达尼布乙磺酸盐, Nintedanib Ethanesulfonate Salt, BIBF 1120

Nintedanib esylate (BIBF 1120 esylate) 是一种有效的三重血管激酶抑制剂,能够抑制 VEGFR1 (IC50:34 nM)、VEGFR2 (IC50:13 nM)、VEGFR3 (IC50:13 nM),FGFR1 (IC50:69 nM)、FGFR2 (IC50:37 nM)、FGFR3 (IC50:108 nM),PDGFRα (IC50:59 nM)、PDGFRβ (IC50:65 nM)。

Nintedanib esylate

Nintedanib esylate

纯度: 99.96%
产品编号 T5001 别名 乙磺酸尼达尼布, Intedanib, BIBF 1120 (esylate), 尼达尼布乙磺酸盐, Nintedanib Ethanesulfonate Salt, BIBF 1120Cas号 656247-18-6

Nintedanib esylate (BIBF 1120 esylate) 是一种有效的三重血管激酶抑制剂,能够抑制 VEGFR1 (IC50:34 nM)、VEGFR2 (IC50:13 nM)、VEGFR3 (IC50:13 nM),FGFR1 (IC50:69 nM)、FGFR2 (IC50:37 nM)、FGFR3 (IC50:108 nM),PDGFRα (IC50:59 nM)、PDGFRβ (IC50:65 nM)。

规格价格库存数量
1 mg¥ 108现货
5 mg¥ 198现货
10 mg¥ 322现货
25 mg¥ 529现货
50 mg¥ 787现货
100 mg¥ 1,160现货
500 mg¥ 2,880现货
1 mL x 10 mM (in DMSO)¥ 293现货
大包装 & 定制
加入购物车
实验操作小课堂
查看更多

"Nintedanib esylate"的相关化合物库

选择批次:
纯度:99.96%
联系我们获取更多批次信息
TargetMol 的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。

产品介绍

生物活性
产品描述
Nintedanib esylate (BIBF 1120 esylate) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β
靶点活性
PDGFRβ:65 nM, PDGFRα:59 nM, FGFR3:108 nM, FGFR1:69 nM, FGFR2:37 nM, VEGFR1:34 nM, VEGFR3:13 nM, VEGFR2:13 nM
体外活性
BIBF 1120 binds to the ATP-binding site in the cleft between the amino and carboxy terminal lobes of the kinase domain. BIBF 1120 inhibits proliferation of PDGF-BB stimulated BRPs with EC50 of 79 nM in cell assays. BIBF1120 (100 nM) blocks activation of MAPK after stimulation with 5% serum plus PDGF-BB. BIBF1120 prevents PDGF-BB stimulated proliferation with an EC50 of 69 nM in cultures of human vascular smooth muscle cells (HUASMC).
体内活性
BIBF1120 (25-100 mg/kg daily p.o.) is highly active in all tumor models, including human tumor xenografts growing in nude mice and a syngeneic rat tumor model. This is evident in the magnetic resonance imaging of tumor perfusion after 3 days, reducing vessel density and vessel integrity after 5 days, and profound growth inhibition. BIBF1120 is orally available and displays encouraging efficacy in in vivo tumor models while being well tolerated.
激酶实验
Enzyme activity is assayed in the presence or absence of serial dilutions of BIBF1120 performed in 25% DMSO. Each microtiter plate contains internal controls such as blank, maximum reaction, and historical reference compound. All incubations are conducted at room temperature on a rotation shaker. 10 μL of each BIBF1120 dilution is added to 10 μL of diluted kinase (0.8 μg/mL VEGFR2, 10 mM Tris pH 7.5, 2 mM EDTA, and 2 mg/mL BSA) and preincubated for 1 hour. The reaction is started by addition of 30 μL of substrate mix containing 62.4 mM Tris pH 7.5, 2.7 mM DTT, 5.3 mM MnCl2, 13.3 mM Mg-acetate, 0.42 mM ATP, 0.83 mg/mL Poly-Glu-Tyr(4:1), and 1.7 μg/mL Poly-Glu-Tyr(4:1)-biotin and incubated for 1 hour. The reaction is stopped by addition of 50 μL of 250 mM EDTA, 20 mM HEPES, pH 7.4. 90 μL of the reaction mix is transferred to a streptavidin plate and incubated for 1-2 hours. After three washes with PBS the EU-labeled antibody, PY20 is added (recommended dilution 1:2000 of 0.5 mg/mL labeled antibody in DELFIA assay buffer). Excessive detection antibody is removed by three ishes of DELFIA washing buffer. Then 10 minutes before measurement on the multilabel reader, each well is incubated with 100 μL of DELFIA enhancement solution.
动物实验
Five-week-old to 6-wk-old athymic NMRI-nu/nu female mice (21-31 g) are used for the assay. After acclimatization, mice are inoculated with 1 to 5×106 (in 100 μL) FaDu, Caki-1, SKOV-3, H460, HT-29, or PAC-120 cells s.c. into the right flank of the animal. After acclimatization, F344 Fischer rats are injected with 5×106 (in 100 μL) GS-9L cells s.c. into the right flank of the animal. For pharmacokinetic analysis, blood is isolated at indicated time points from the retroorbital plexus of mice and plasma is analyzed using high performance liquid chromatography-mass spectrometry methodology.
别名乙磺酸尼达尼布, Intedanib, BIBF 1120 (esylate), 尼达尼布乙磺酸盐, Nintedanib Ethanesulfonate Salt, BIBF 1120
化学信息
分子量649.76
分子式C31H33N5O4.C2H6O3S
CAS No.656247-18-6
储存&溶解度
存储keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
溶解度信息
DMSO: 45 mg/mL (69.26 mM), Sonication and heating are recommended.
溶液配制表
DMSO
1mg5mg10mg50mg
1 mM1.5390 mL7.6951 mL15.3903 mL76.9515 mL
5 mM0.3078 mL1.5390 mL3.0781 mL15.3903 mL
10 mM0.1539 mL0.7695 mL1.5390 mL7.6951 mL
20 mM0.0770 mL0.3848 mL0.7695 mL3.8476 mL
50 mM0.0308 mL0.1539 mL0.3078 mL1.5390 mL

计算器

  • 摩尔浓度 计算器
  • 稀释 计算器
  • 配液 计算器
  • 分子量 计算器

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
TargetMol | Animal experiments比如您的给药剂量是 10 mg/kg ,每只动物体重 20 g ,给药体积 100 μLTargetMol | Animal experiments 一共给药动物 10 只 ,您使用的配方为 5% TargetMol | reagent DMSO+ 30%PEG300+ 5%Tween 80 + 60% ddH2O. 那么您的工作液浓度为 2 mg/mL
母液配置方法: 2 mg 药物溶于 50 μLDMSOTargetMol | reagent ( 母液浓度为 40 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:50μLDMSOTargetMol | reagent 母液,添加 300 μLPEG300TargetMol | reagent 混匀澄清,再加 50μLTween 80, 混匀澄清,再加 600μLddH2OTargetMol | reagent 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

1 请输入动物实验的基本信息
mg/kg
g
μL
2 请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
%Tween 80
%ddH2O

剂量转换

对于不同动物的给药剂量换算,您也可以参考 更多

关键词

Related Tags: buy Nintedanib esylate | purchase Nintedanib esylate | Nintedanib esylate cost | order Nintedanib esylate | Nintedanib esylate chemical structure | Nintedanib esylate in vivo | Nintedanib esylate in vitro | Nintedanib esylate formula | Nintedanib esylate molecular weight